Medullary Thyroid Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Medullary Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Medullary thyroid cancer (MTC) is a rare and aggressive type of thyroid cancer that originates from the C cells, which produce calcitonin, a hormone that regulates calcium levels in the blood. MTC accounts for 5-10% of all thyroid cancers and can be sporadic or inherited. Sporadic MTC occurs randomly, while inherited MTC is associated with a genetic condition called multiple endocrine neoplasia type 2 (MEN2). Symptoms of MTC may include a lump in the neck, hoarseness, diarrhea, and flushing. The main treatment for MTC is surgery to remove the thyroid gland and sometimes the nearby lymph nodes. Other treatments, such as radiation or medication, may be used depending on the stage and spread of the cancer. Early detection and treatment of MTC can improve the prognosis and quality of life of patients.
The Medullary Thyroid Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Medullary Thyroid Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 48 molecules, with 39 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Medullary Thyroid Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Medullary Thyroid Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Medullary Thyroid Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Advenchen Laboratories LLCAffyImmune Therapeutics Inc
Applied Pharmaceutical Science Inc
AstraZeneca Plc
Bayer AG
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
C4 Therapeutics Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Ellipses Pharma Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Full-Life Technologies Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
HEC Pharma Co Ltd
ImmunityBio Inc
IngenoVax LLC
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd
Johnson & Johnson
Juntendo University Hospital
Kite Pharma Inc
KLUS Pharma Inc
Loxo Oncology Inc
Novartis AG
Perspective Therapeutics Inc
Public Univeristy Hospital of Pisana
Recordati SpA
Shanghai Jiao Tong University School of Medicine
Shouyao Holding Co Ltd
Synactix Pharmaceuticals Inc
TYK Medicines Inc
Tyra Biosciences Inc
University of Arkansas for Medical Sciences
University of Florida
University of Pisa
Xynomic Pharmaceuticals Holdings Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Medullary Thyroid Cancer reports